BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bolder BioTechnology, Inc. Awarded National Institutes of Health (NIH) Phase I SBIR Grant To Develop Bioscavenger Protein For Detoxifying Nerve Agents


10/19/2005 5:13:19 PM

WHEAT RIDGE, Colo., Oct. 10 /PRNewswire/ -- Bolder BioTechnology, Inc. today announced that it has been awarded a $121,844 Phase I Small Business Innovation Research (SBIR) grant from The National Institute of General Medical Sciences of The National Institutes of Health. The grant provides funds to optimize the pharmacological properties of a human enzyme, butyrylcholinesterase, which is capable of inactivating toxic organophosphorus nerve agents such as Soman, Sarin and VX. The optimized butyrylcholinesterase protein may have applications in Biodefense as a bioscavenger protein for detoxifying nerve agents, and as a treatment for patients with cocaine or heroin drug overdoses.

The SBIR program is a peer-reviewed grant program that provides research support to small businesses to discover and develop innovative biomedical products for the treatment of serious unmet medical needs. Companies that successfully meet the goals of the Phase I grant are eligible to apply for an additional $750,000 in Phase II grant support to continue their product development efforts.

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site at www.bolderbio.com.

Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.

Bolder BioTechnology, Inc.

CONTACT: Joe Cox, Ph.D., President of Bolder BioTechnology, Inc.,+1-303-420-4420, ext. 101



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES